Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Gelectin Therapeutics ($GALT) stock shot up as the company announced receiving a notice of allowance from the USPTO for a patent covering method of use of lead product candidate GR-MD-02 as a means to enhance anti-tumor activity and increase survival effects of combining GR-MD-02 with multiple immune modulators for multiple types of cancer. With this new win, the company now has 17 US patents in its portfolio. The patent also covers the ability of GR-MD-02 to enhance the effectiveness of immune modulators in a variety of cancers, including gastrointestinal cancer, pancreatic cancer and other kind of cancers.
The company stock has gained over 128 percent this year so far.

Flex Pharma ($FLKS) announced receiving the Fast Track review status for its FLX-787 from the FDA. The drug is being tested for treating muscle cramps associated with amyotrophic lateral sclerosis. There are currently no drugs approved in the US for this condition. The company plans to start a Phase 2 study from this quarter. The new status will allow the rolling review of the company’s New Drug Application. Through the Fast Track program, a product may be eligible for priority review at the time of a New Drug Application filing.
The company stock gained over 15 percent in its previous trading session.


Neuralstem ($CUR) reported that its NSI-189 failed to demonstrate a treatment benefit in a Phase 2 clinical trial in patients with major depressive disorder. Specifically, treatment with NSI-189 failed to show a significant reduction in depression symptoms as measured by a scale called MADRS.

EnteroMedics ($ETRM) announced the first implant of its vBloc Neurometabolic Therapy at the Methodist Dallas Medical Center. The procedure was provided through the Veterans Choice Program which allows veterans to have the vBloc procedure at a local facility.

Bristol Myers Squibb ($BMY) announced receiving the approval from the European Commission for its Orencia as monotherapy or in combination with methotrexate, for the treatment of adult patients with active psoriatic arthritis. ORENCIA is already approved in Europe for the treatment of rheumatoid arthritis and polyarticular juvenile idiopathic arthritis.

Ablynx ($ABYLY) received the Fast Track status from the FDA for caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. A Phase 3 clinical trial, HERCULES, is likely to be completed by October. The company expects to file its U.S. marketing application in 2018.


CryoPort ($CYRX) reported inking a new collaboration with Novartis. The three year agreement pertains to cryogenic logistics support for CTL019/CD19 CAR-T cell therapy. The companies did not disclose financial terms of the deal. The deal will include the use of its Cryoport Express shippers, SmartPak II Condition Monitoring System.

Cogentix Medical ($CGNT) announced acquiring Genesis Medical, a London based firm engaged in the marketing of products to urologists in the UK. The firms did not disclose the financial terms of the deal. Genesis Medical has been the exclusive distributor of Cogentix's PrimeSight endoscopy systems since 2013.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Citigroup Raises Target Allergan PLC. (AGN)
Buy $290.00 Low

Piper Jaffray Companies Reiterates Akamai Technologies (AKAM)
Buy $57.00 High

Piper Jaffray Companies Reiterates Autoliv (ALV)
Hold $99.00 Low

Robert W. Baird Initiates Advanced Micro Devices (AMD)
Outperform $20.00 High

BMO Capital Markets Downgrades Advanced Micro Devices (AMD)
Outperform -> Market Perform $15.00 High

Mizuho Downgrades Amedisys (AMED)
Buy -> Neutral Low

Gainers (% price change)Last TradeChangeMkt CapInvacare CorporationIVC15.95+3.30 (26.09%)533.11MCompugen Ltd. (USA)CGEN4.05+0.65 (19.12%)200.77MIdera Pharmaceuticals IncIDRA2.06+0.14 (7.29%)313.78MU.S. Physical TherapyUSPH66.75+3.95 (6.29%)847.68MEndologix, Inc.ELGX5.31+0.28 (5.57%)441.48MLosers (% price change)Pacira PharmaceuticalsPCRX42.65-6.05 (-12.42%)1.75BHealthStream, Inc.HSTM22.89-3.10 (-11.93%)729.22MCommunity Health SystemsCYH8.71-0.97 (-10.02%)1.04BTenet Healthcare CorpTHC19.52-1.59 (-7.53%)2.01BDynavax Tech. Corp.DVAX9.90-0.75 (-7.04%)601.28MMost Actives (dollar volume)ResMed Inc.RMD77.68+0.49 (0.63%)11.04BEli Lilly and CoLLY82.19-2.55 (-3.01%)90.77BBiogen IncBIIB282.96-1.74 (-0.61%)60.40BJohnson & JohnsonJNJ131.88-1.13 (-0.85%)349.22BGilead Sciences, Inc.GILD73.74-0.65 (-0.87%)97.18B